We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

By LabMedica International staff writers
Posted on 30 Sep 2026

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. More...

Current analytical methods can be complex, time-consuming, and dependent on specialized personnel, limiting their use for rapid onsite screening. To simplify this type of analysis, new findings demonstrate a laser-based approach that detects disease-associated odor signatures from simple swab samples.

The Fraunhofer Institute for Integrated Circuits IIS (Erlangen, Germany) and the Technical University of Dresden tested laser-based photoacoustic spectroscopy for detecting volatile organic compound patterns linked to disease. The measurement system developed at Fraunhofer IIS uses widely tunable quantum cascade lasers and a sensitive photoacoustic detector. The system generates characteristic spectral fingerprints of volatile organic compounds from swab samples taken from the anterior nasal cavity, navel, and outer ear, with nasal swabs described as particularly promising.

The proof-of-concept study was conducted under controlled laboratory conditions using participants randomly selected from the large-scale SMELLODI study. The cohort included 24 participants: six healthy controls, six people with Parkinson’s disease, six people with COVID-19, and six people with other conditions. Additional measurements taken two weeks later from three participants with Parkinson’s disease provided initial evidence that the results were stable over time. Statistical analysis also showed that the measurement scope could be significantly reduced without losing relevant information.

The study found differences between samples from healthy individuals and samples from people with Parkinson’s disease, COVID-19, and other diseases. The results were published in Scientific Reports under the title “Detection of disease-associated VOC signatures with laser-based photoacoustic spectroscopy (LPAS).”

Fraunhofer IIS developed the experimental setup, performed laboratory measurements, and conducted statistical analysis, while the Technical University of Dresden contributed medical and clinical expertise and coordinated recruitment, diagnosis, and sample collection. The approach is not yet a substitute for medical diagnosis, and larger studies involving more diverse participants under real-world conditions are needed before clinical use.

Related Links
Fraunhofer IIS
Technical University of Dresden


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.